JP2014525402A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014525402A5 JP2014525402A5 JP2014525143A JP2014525143A JP2014525402A5 JP 2014525402 A5 JP2014525402 A5 JP 2014525402A5 JP 2014525143 A JP2014525143 A JP 2014525143A JP 2014525143 A JP2014525143 A JP 2014525143A JP 2014525402 A5 JP2014525402 A5 JP 2014525402A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- neuroprotective agent
- solvent
- item
- microparticle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims description 57
- 239000011859 microparticle Substances 0.000 claims description 51
- 239000004090 neuroprotective agent Substances 0.000 claims description 47
- 208000014674 injury Diseases 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 34
- 239000002904 solvent Substances 0.000 claims description 29
- 239000003607 modifier Substances 0.000 claims description 25
- 239000001961 anticonvulsive agent Substances 0.000 claims description 24
- 239000004094 surface-active agent Substances 0.000 claims description 22
- 239000000243 solution Substances 0.000 claims description 21
- 239000002245 particle Substances 0.000 claims description 19
- 230000008733 trauma Effects 0.000 claims description 18
- 208000027418 Wounds and injury Diseases 0.000 claims description 16
- 230000006378 damage Effects 0.000 claims description 16
- 239000000725 suspension Substances 0.000 claims description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- 230000001773 anti-convulsant effect Effects 0.000 claims description 12
- 229960003965 antiepileptics Drugs 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- 229960000623 carbamazepine Drugs 0.000 claims description 8
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical group C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 8
- 229960003472 felbamate Drugs 0.000 claims description 7
- WKGXYQFOCVYPAC-UHFFFAOYSA-N felbamate Chemical compound NC(=O)OCC(COC(N)=O)C1=CC=CC=C1 WKGXYQFOCVYPAC-UHFFFAOYSA-N 0.000 claims description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- 208000012902 Nervous system disease Diseases 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 238000007911 parenteral administration Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 206010021143 Hypoxia Diseases 0.000 claims description 4
- 208000025966 Neurological disease Diseases 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 4
- 230000007954 hypoxia Effects 0.000 claims description 4
- 208000028867 ischemia Diseases 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 230000009529 traumatic brain injury Effects 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 2
- 206010010904 Convulsion Diseases 0.000 claims description 2
- 208000028389 Nerve injury Diseases 0.000 claims description 2
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 229960005150 glycerol Drugs 0.000 claims description 2
- 239000011874 heated mixture Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000008764 nerve damage Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229940068886 polyethylene glycol 300 Drugs 0.000 claims description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims description 2
- 229940057847 polyethylene glycol 600 Drugs 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 229940068977 polysorbate 20 Drugs 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000002002 slurry Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000010419 fine particle Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161522811P | 2011-08-12 | 2011-08-12 | |
| US61/522,811 | 2011-08-12 | ||
| PCT/US2012/050148 WO2013025442A2 (en) | 2011-08-12 | 2012-08-09 | Concentrated felbamate formulations for parenteral administration |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017079599A Division JP2017122127A (ja) | 2011-08-12 | 2017-04-13 | 非経口投与のための濃縮されたフェルバメート製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014525402A JP2014525402A (ja) | 2014-09-29 |
| JP2014525402A5 true JP2014525402A5 (enExample) | 2015-09-24 |
Family
ID=47715640
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014525143A Withdrawn JP2014525402A (ja) | 2011-08-12 | 2012-08-09 | 非経口投与のための濃縮されたフェルバメート製剤 |
| JP2017079599A Ceased JP2017122127A (ja) | 2011-08-12 | 2017-04-13 | 非経口投与のための濃縮されたフェルバメート製剤 |
| JP2019022430A Pending JP2019085416A (ja) | 2011-08-12 | 2019-02-12 | 非経口投与のための濃縮されたフェルバメート製剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017079599A Ceased JP2017122127A (ja) | 2011-08-12 | 2017-04-13 | 非経口投与のための濃縮されたフェルバメート製剤 |
| JP2019022430A Pending JP2019085416A (ja) | 2011-08-12 | 2019-02-12 | 非経口投与のための濃縮されたフェルバメート製剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20140178479A1 (enExample) |
| EP (1) | EP2741751A4 (enExample) |
| JP (3) | JP2014525402A (enExample) |
| AU (1) | AU2012295390B2 (enExample) |
| CA (1) | CA2844907A1 (enExample) |
| HK (1) | HK1198942A1 (enExample) |
| WO (1) | WO2013025442A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE041426T2 (hu) | 2009-11-02 | 2019-05-28 | Univ Washington | Terápiás nukleáz-készítmények és eljárások |
| CA2834626A1 (en) | 2011-04-29 | 2012-11-01 | University Of Washington | Therapeutic nuclease compositions and methods |
| SI3063275T1 (sl) | 2013-10-31 | 2020-02-28 | Resolve Therapeutics, Llc | Terapevtske fuzije nukleaza-albumin in postopki |
| WO2015100252A1 (en) * | 2013-12-23 | 2015-07-02 | Perosphere, Inc. | Deuterated felbamate, compositions containing the same, and methods of use thereof |
| GB201604359D0 (en) * | 2016-03-15 | 2016-04-27 | Univ Newcastle | Treatment of tissue disorders |
| MA45554A (fr) | 2016-07-01 | 2019-05-08 | Resolve Therapeutics Llc | Fusions de binucléase optimisées. |
| CN111315767B (zh) | 2017-08-22 | 2025-03-18 | 萨纳生物有限责任公司 | 可溶性干扰素受体及其用途 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1904257A (en) * | 1926-10-29 | 1933-04-18 | Firm Of Chemical Works Formerl | Supersaturated calcium gluconate solution |
| US3017323A (en) * | 1957-07-02 | 1962-01-16 | Pfizer & Co C | Therapeutic compositions comprising polyhydric alcohol solutions of tetracycline-type antibiotics |
| US5308621A (en) * | 1991-02-18 | 1994-05-03 | Commonwealth Scientific And Industrial Research Organisation | Ascorbic acid composition and transdermal administration method |
| US6020367A (en) * | 1997-12-02 | 2000-02-01 | Avon Products, Inc. | Supersaturated ascorbic acid solutions |
| JP2002536409A (ja) * | 1999-02-09 | 2002-10-29 | ユニバーシティ オブ バージニア パテント ファウンデーション | フェルバメートから誘導される化合物 |
| AU5967101A (en) | 2000-05-10 | 2001-11-20 | Rtp Pharma Inc | Media milling |
| US20040256749A1 (en) * | 2000-12-22 | 2004-12-23 | Mahesh Chaubal | Process for production of essentially solvent-free small particles |
| US20040022862A1 (en) | 2000-12-22 | 2004-02-05 | Kipp James E. | Method for preparing small particles |
| JP4732696B2 (ja) | 2002-04-09 | 2011-07-27 | フラメル・テクノロジー | 活性成分の改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤 |
| EP1594515A4 (en) * | 2003-02-03 | 2009-05-27 | Supernus Pharmaceuticals Inc | FORMULATION AND ADMINISTRATION OF A MEDICINAL PRODUCT USING METHYLATED CRYSTALLINE CYCLODEXTRINS |
| AU2004240640A1 (en) * | 2003-05-19 | 2004-12-02 | Baxter International Inc. | Solid particles comprising an anticonvulsant or an immunosuppressive coated with one or more surface modifiers |
| WO2004105699A2 (en) | 2003-05-28 | 2004-12-09 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage |
| MY142989A (en) * | 2004-03-10 | 2011-02-14 | Bayer Schering Pharma Ag | Stabilised supersaturated solids of lipophilic drugs |
| WO2007041524A2 (en) * | 2005-09-30 | 2007-04-12 | Ovation Pharmaceuticals, Inc. | Novel parenteral carbamazepine formulation |
| AU2007207606A1 (en) * | 2006-01-17 | 2007-07-26 | Regents Of The University Of Colorado | Central administration of stable formulations of therapeutic agents for CNS conditions |
| GB0607105D0 (en) * | 2006-04-10 | 2006-05-17 | Leuven K U Res & Dev | Enhancing solubility and dissolution rate of poorly soluble drugs |
| WO2009017825A2 (en) | 2007-08-02 | 2009-02-05 | The General Hospital Corporation | Novel lipoxygenase inhibitors as neuroprotective agents |
| CA2720254A1 (en) * | 2008-04-01 | 2009-12-17 | Regents Of The University Of Colorado, A Body Corporate | Methods and compositions for the intracerebroventricular administration of felbamate |
| US8637569B2 (en) * | 2009-10-22 | 2014-01-28 | Api Genesis, Llc | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds |
| AU2012250050B2 (en) * | 2011-04-28 | 2017-04-06 | Platform Brightworks Two, Ltd. | Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same |
-
2012
- 2012-04-09 US US14/238,138 patent/US20140178479A1/en not_active Abandoned
- 2012-08-09 HK HK14112610.9A patent/HK1198942A1/xx unknown
- 2012-08-09 WO PCT/US2012/050148 patent/WO2013025442A2/en not_active Ceased
- 2012-08-09 JP JP2014525143A patent/JP2014525402A/ja not_active Withdrawn
- 2012-08-09 CA CA2844907A patent/CA2844907A1/en not_active Abandoned
- 2012-08-09 AU AU2012295390A patent/AU2012295390B2/en not_active Ceased
- 2012-08-09 EP EP12824467.0A patent/EP2741751A4/en not_active Withdrawn
-
2017
- 2017-02-21 US US15/438,530 patent/US20170157083A1/en not_active Abandoned
- 2017-04-13 JP JP2017079599A patent/JP2017122127A/ja not_active Ceased
-
2019
- 2019-02-12 JP JP2019022430A patent/JP2019085416A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mehanna et al. | Rifampicin-carbohydrate spray-dried nanocomposite: a futuristic multiparticulate platform for pulmonary delivery | |
| CN105902496B (zh) | 一种纳米混悬液固体化过程的处理方法 | |
| Dizaj et al. | Nanosizing of drugs: effect on dissolution rate | |
| CN1293570A (zh) | 紫杉烷的药物制剂 | |
| CN104224723A (zh) | 一种泊马度胺纳米粒、制剂及其制备方法 | |
| JP2019526542A5 (enExample) | ||
| JP2013542205A5 (enExample) | ||
| US20130172283A1 (en) | Lyophilized formulation of pectin-adriamycin conjugate and preparation method thereof | |
| KR20210007924A (ko) | 리바스티그민을 포함하는 장기지속형 제제 및 이의 제조방법 | |
| CN110638752A (zh) | 注射剂 | |
| JP2011507838A5 (enExample) | ||
| Mansour et al. | Intranasal versus intraperitoneal Myrj 59-stabilized cubosomes: a potential armamentarium of effective anti-diabetic therapy | |
| Aguilar-Hernández et al. | Nanosuspensions as carriers of active ingredients: Chemical composition, development methods, and their biological activities | |
| HK1198942A1 (en) | Concentrated felbamate formulations for parenteral administration | |
| JP2015520241A5 (enExample) | ||
| CN101843582B (zh) | 紫杉醇纳米混悬剂及其制备方法 | |
| Guo et al. | Preparation, optimization of intravenous ZL-004 nanosuspensions by the precipitation method, effect of particle size on in vivo pharmacokinetics and tissue distribution | |
| CN102961368A (zh) | 一种姜黄素纳米混悬剂及其制备方法 | |
| CN103110594A (zh) | 一种阿托伐他汀钙纳米冻干粉及其制备方法 | |
| CN101961320A (zh) | 布地奈德纳米结晶制剂及其制备方法 | |
| CN104511020A (zh) | 一种紫杉醇的药物组合物 | |
| CN103251556A (zh) | 一种阿瑞吡坦纳米混悬剂及其制备方法 | |
| CN103356480B (zh) | 一种齐墩果酸纳米混悬剂及其制备方法 | |
| CN109369343B (zh) | 一种和厚朴酚纳晶的制备方法 | |
| WO2015154677A1 (zh) | 药物组合物及其应用 |